Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge

PLoS Neglected Tropical Diseases

Volumn 12, Issue 7, 2018, Pages

  Zivcec, Marko ^a,b,c   Safronetz, David ^a,b,d   Scott, Dana P ^b   Robertson, Shelly ^b   Feldmann, Heinz ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VACCINE; GENOMIC RNA; NUCLEOCAPSID PROTEIN; NUCLEOCAPSID PROTEIN BASED VACCINE; UNCLASSIFIED DRUG; VIRUS RNA; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DISTRIBUTION; ANTIGEN EXPRESSION; ARTICLE; BODY WEIGHT FLUCTUATION; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER; CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; IMMUNOBLOTTING; IMMUNOCOMPROMISED MOUSE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SW13 CELL LINE; TCID50; VACCINATION; VACCINE EFFICACY; VACCINE IMMUNOGENICITY; VIREMIA; VIRUS LOAD; ANIMAL; C57BL MOUSE; DISEASE MODEL; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; MALE; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; FEMALE; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; MALE; MICE; MICE, INBRED C57BL; NUCLEOCAPSID PROTEINS; VIRAL VACCINES;

EID: 85051291022     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0006628     Document Type: Article

References (39)

1. Ergonul O, Crimean-Congo haemorrhagic fever. Lancet Infect Dis. 2006;6(4):203–14. doi: 10.1016/S1473-3099(06)70435-2 pmid: 16554245.
2. Bente DA, Forrester NL, Watts DM, McAuley AJ, Whitehouse CA, Bray M, Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res. 2013;100(1):159–89. doi: 10.1016/j.antiviral.2013.07.006 pmid: 23906741.
3. Zivcec M, Scholte FE, Spiropoulou CF, Spengler JR, Bergeron E, Molecular Insights into Crimean-Congo Hemorrhagic Fever Virus. Viruses. 2016;8(4):106. doi: 10.3390/v8040106 pmid: 27110812; PubMed Central PMCID: PMCPMC4848600.
4. Vorou R, Pierroutsakos IN, Maltezou HC, Crimean-Congo hemorrhagic fever. Curr Opin Infect Dis. 2007;20(5):495–500. doi: 10.1097/QCO.0b013e3282a56a0a pmid: 17762783.
5. Shepherd AJ, Leman PA, Swanepoel R, Viremia and antibody response of small African and laboratory animals to Crimean-Congo hemorrhagic fever virus infection. Am J Trop Med Hyg. 1989;40(5):541–7. pmid: 2499205.
6. Papa A, Mirazimi A, Koksal I, Estrada-Pena A, Feldmann H, Recent advances in research on Crimean-Congo hemorrhagic fever. J Clin Virol. 2015;64:137–43. doi: 10.1016/j.jcv.2014.08.029 pmid: 25453328; PubMed Central PMCID: PMCPMC4346445.
7. Andersson I, Bladh L, Mousavi-Jazi M, Magnusson KE, Lundkvist A, Haller O, et al. Human MxA protein inhibits the replication of Crimean-Congo hemorrhagic fever virus. J Virol. 2004;78(8):4323–9. doi: 10.1128/JVI.78.8.4323-4329.2004 pmid: 15047845; PubMed Central PMCID: PMCPMC374267.
8. Andersson I, Lundkvist A, Haller O, Mirazimi A, Type I interferon inhibits Crimean-Congo hemorrhagic fever virus in human target cells. J Med Virol. 2006;78(2):216–22. doi: 10.1002/jmv.20530 pmid: 16372299.
9. Simon M, Falk KI, Lundkvist A, Mirazimi A, Exogenous nitric oxide inhibits Crimean Congo hemorrhagic fever virus. Virus Res. 2006;120(1–2):184–90. doi: 10.1016/j.virusres.2006.03.005 pmid: 16632039.
10. Bente DA, Alimonti JB, Shieh WJ, Camus G, Stroher U, Zaki S, et al. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J Virol. 2010;84(21):11089–100. doi: 10.1128/JVI.01383-10 pmid: 20739514; PubMed Central PMCID: PMCPMC2953203.
11. Bereczky S, Lindegren G, Karlberg H, Akerstrom S, Klingstrom J, Mirazimi A, Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice. J Gen Virol. 2010;91(Pt 6):1473–7. doi: 10.1099/vir.0.019034-0 pmid: 20164263.
12. Zivcec M, Safronetz D, Scott D, Robertson S, Ebihara H, Feldmann H, Lethal Crimean-Congo hemorrhagic fever virus infection in interferon alpha/beta receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy. J Infect Dis. 2013;207(12):1909–21. doi: 10.1093/infdis/jit061 pmid: 23417661; PubMed Central PMCID: PMCPMC3654741.
13. Atkinson B, Latham J, Chamberlain J, Logue C, O'Donoghue L, Osborne J, et al. Sequencing and phylogenetic characterisation of a fatal Crimean—Congo haemorrhagic fever case imported into the United Kingdom, October 2012. Euro Surveill. 2012;17(48). pmid: 23218389.
14. Lumley S, Atkinson B, Dowall S, Pitman J, Staplehurst S, Busuttil J, et al. Non-fatal case of Crimean-Congo haemorrhagic fever imported into the United Kingdom (ex Bulgaria), June 2014. Euro Surveill. 2014;19(30). pmid: 25108534.
15. Conger NG, Paolino KM, Osborn EC, Rusnak JM, Gunther S, Pool J, et al. Health care response to CCHF in US soldier and nosocomial transmission to health care providers, Germany, 2009. Emerg Infect Dis. 2015;21(1):23–31. doi: 10.3201/eid2101.141413 pmid: 25529825; PubMed Central PMCID: PMCPMC4285246.
16. Yadav PD, Thacker S, Patil DY, Jain R, Mourya DT, Crimean-Congo Hemorrhagic Fever in Migrant Worker Returning from Oman to India, 2016. Emerg Infect Dis. 2017;23(6):1005–8. doi: 10.3201/eid2306.161950 pmid: 28518037; PubMed Central PMCID: PMCPMC5443448.
17. Midilli K, Gargili A, Ergonul O, Sengoz G, Ozturk R, Bakar M, et al. Imported Crimean-Congo hemorrhagic fever cases in Istanbul. BMC Infect Dis. 2007;7:54. doi: 10.1186/1471-2334-7-54 pmid: 17553137; PubMed Central PMCID: PMCPMC1905914.
18. Estrada-Pena A, Jameson L, Medlock J, Vatansever Z, Tishkova F, Unraveling the ecological complexities of tick-associated Crimean-Congo hemorrhagic fever virus transmission: a gap analysis for the western Palearctic. Vector Borne Zoonotic Dis. 2012;12(9):743–52. doi: 10.1089/vbz.2011.0767 pmid: 22448676.
19. Estrada-Pena A, Ruiz-Fons F, Acevedo P, Gortazar C, de la Fuente J, Factors driving the circulation and possible expansion of Crimean-Congo haemorrhagic fever virus in the western Palearctic. J Appl Microbiol. 2013;114(1):278–86. doi: 10.1111/jam.12039 pmid: 23061817.
20. Dowall SD, Buttigieg KR, Findlay-Wilson SJ, Rayner E, Pearson G, Miloszewska A, et al. A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease. Hum Vaccin Immunother. 2016;12(2):519–27. doi: 10.1080/21645515.2015.1078045 pmid: 26309231.
21. Buttigieg KR, Dowall SD, Findlay-Wilson S, Miloszewska A, Rayner E, Hewson R, et al. A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model. PLoS One. 2014;9(3):e91516. doi: 10.1371/journal.pone.0091516 pmid: 24621656; PubMed Central PMCID: PMCPMC3951450.
22. Kortekaas J, Vloet RP, McAuley AJ, Shen X, Bosch BJ, de Vries L, et al. Crimean-Congo Hemorrhagic Fever Virus Subunit Vaccines Induce High Levels of Neutralizing Antibodies But No Protection in STAT1 Knockout Mice. Vector Borne Zoonotic Dis. 2015;15(12):759–64. doi: 10.1089/vbz.2015.1855 pmid: 26684523.
23. Canakoglu N, Berber E, Tonbak S, Ertek M, Sozdutmaz I, Aktas M, et al. Immunization of knock-out alpha/beta interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine. PLoS Negl Trop Dis. 2015;9(3):e0003579. doi: 10.1371/journal.pntd.0003579 pmid: 25760444; PubMed Central PMCID: PMCPMC4356576.
24. Hinkula J, Devignot S, Akerstrom S, Karlberg H, Wattrang E, Bereczky S, et al. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice. J Virol. 2017;91(10). doi: 10.1128/JVI.02076-16 pmid: 28250124; PubMed Central PMCID: PMCPMC5411611.
25. Garrison AR, Shoemaker CJ, Golden JW, Fitzpatrick CJ, Suschak JJ, Richards MJ, et al. A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models. PLoS Negl Trop Dis. 2017;11(9):e0005908. doi: 10.1371/journal.pntd.0005908 pmid: 28922426.
26. Goedhals D, Bester PA, Paweska JT, Swanepoel R, Burt FJ, Next-generation sequencing of southern African Crimean-Congo haemorrhagic fever virus isolates reveals a high frequency of M segment reassortment. Epidemiol Infect. 2014;142(9):1952–62. doi: 10.1017/S0950268814000818 pmid: 24786748.
27. Ozdarendeli A, Canakoglu N, Berber E, Aydin K, Tonbak S, Ertek M, et al. The complete genome analysis of Crimean-Congo hemorrhagic fever virus isolated in Turkey. Virus Res. 2010;147(2):288–93. doi: 10.1016/j.virusres.2009.11.009 pmid: 19941917.
28. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, Strong JE, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One. 2008;3(10):e3548. Epub 2008/10/30. doi: 10.1371/journal.pone.0003548 pmid: 18958172; PubMed Central PMCID: PMC2569416.
29. Spengler JR, Keating MK, McElroy AK, Zivcec M, Coleman-McCray JD, Harmon JR, et al. Crimean-Congo Hemorrhagic Fever in Humanized Mice Reveals Glial Cells as Primary Targets of Neurological Infection. J Infect Dis. 2017. doi: 10.1093/infdis/jix215 pmid: 28482001.
30. Wernike K, Breithaupt A, Keller M, Hoffmann B, Beer M, Eschbaumer M, Schmallenberg virus infection of adult type I interferon receptor knock-out mice. PLoS One. 2012;7(7):e40380. Epub 2012/07/14. doi: 10.1371/journal.pone.0040380 pmid: 22792298; PubMed Central PMCID: PMC3391294.
31. Calvo-Pinilla E, Rodriguez-Calvo T, Anguita J, Sevilla N, Ortego J, Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor. PLoS One. 2009;4(4):e5171. Epub 2009/04/10. doi: 10.1371/journal.pone.0005171 pmid: 19357779; PubMed Central PMCID: PMC2663843.
32. Frenz T, Waibler Z, Hofmann J, Hamdorf M, Lantermann M, Reizis B, et al. Concomitant type I IFN receptor-triggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankara-induced T-cell expansion. European journal of immunology. 2010;40(10):2769–77. Epub 2010/09/08. doi: 10.1002/eji.201040453 pmid: 20821729.
33. Winkelmann ER, Widman DG, Xia J, Ishikawa T, Miller-Kittrell M, Nelson MH, et al. Intrinsic adjuvanting of a novel single-cycle flavivirus vaccine in the absence of type I interferon receptor signaling. Vaccine. 2012;30(8):1465–75. Epub 2012/01/10. doi: 10.1016/j.vaccine.2011.12.103 pmid: 22226862; PubMed Central PMCID: PMC3274573.
34. Pinto AK, Daffis S, Brien JD, Gainey MD, Yokoyama WM, Sheehan KC, et al. A temporal role of type I interferon signaling in CD8+ T cell maturation during acute West Nile virus infection. PLoS pathogens. 2011;7(12):e1002407. Epub 2011/12/07. doi: 10.1371/journal.ppat.1002407 pmid: 22144897; PubMed Central PMCID: PMC3228803.
35. Raaben M, Groot Koerkamp MJ, Rottier PJ, de Haan CA, Type I interferon receptor-independent and -dependent host transcriptional responses to mouse hepatitis coronavirus infection in vivo. BMC genomics. 2009;10:350. Epub 2009/08/05. doi: 10.1186/1471-2164-10-350 pmid: 19650917; PubMed Central PMCID: PMC2728740.
36. Dowall SD, Graham VA, Rayner E, Hunter L, Watson R, Taylor I, et al. Protective effects of a Modified Vaccinia Ankara-based vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responses. PLoS One. 2016;11(6):e0156637. doi: 10.1371/journal.pone.0156637 pmid: 27272940; PubMed Central PMCID: PMCPMC4896484.
37. Hensley SE, Cun AS, Giles-Davis W, Li Y, Xiang Z, Lasaro MO, et al. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Molecular therapy: the journal of the American Society of Gene Therapy. 2007;15(2):393–403. Epub 2007/01/20. doi: 10.1038/sj.mt.6300024 pmid: 17235319.
38. Martin V, Pascual E, Avia M, Pena L, Valcarcel F, Sevilla N, Protective Efficacy in Sheep of Adenovirus-Vectored Vaccines against Bluetongue Virus Is Associated with Specific T Cell Responses. PLoS One. 2015;10(11):e0143273. Epub 2015/12/01. doi: 10.1371/journal.pone.0143273 pmid: 26619062; PubMed Central PMCID: PMCPMC4664254.
39. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386(9996):857–66. doi: 10.1016/S0140-6736(15)61117-5 pmid: 26248676.